))
NSAIDs, Part 3: The rise, fall and rise again of COX-2 inhibition
Manage episode 436874438 series 3560282
Contenido proporcionado por Healio, Adam J. Brown, and MD. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Healio, Adam J. Brown, and MD o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?
- Intro 0:11
- Recap of part 1 & 2 0:28
- In this episode 1:44
- Cyclooxygenase 2 (COX-2) and the rat experiment 3:12
- What do we know about the prostaglandins? And what about COX-2 7:54
- What does prostacyclin do? 10:33
- The first COX-2 inhibitor: VIOXX 10:56
- What is COX-2 doing?: Pfizer and Merck 12:15
- Two more NSAID studies: colon cancer, Alzheimer’s disease and COX-2 inhibitors 18:41
- VIOXX: Why is myocardial infarction risk occurring? 22:34
- Animal models and the Goldilocks theory of thromboxane and prostacyclin 23:49
- PRECISION trial 30:25
- Rheum + Boards 37:14
- Thanks for listening 37:32
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
References:
Anderson GD, et al. J Clin Invest. 1996;doi:10.1172/JCI118717.
Funk CD, et al. J Cardiovasc Pharmacol. 2007;doi:10.1097/FJC.0b013e318157f72d.
Hennan JK, et al. Circulation. 2001;doi:10.1161/hc3301.092790.
Krumholz HM, et al. BMJ. 2007;doi:10.1136/bmj.39024.487720.68.
Nissen SE, et al. N Engl J Med. 2016;doi:10.1056/NEJMoa1611593.
Disclosures: Brown reports no relevant financial disclosures.
85 episodios
Compartir
